LIFESCAPES is a researcher and manufacturer of brain-computer interface equipment. LIFESCAPES aims to use BMI technology to help stroke patients solve problems and improve their quality of life. LIFESCAPES uses BMI to bring out the plasticity of the brain and help people who are in trouble to be free of their limitations and to live their lives normally.
K Pharma is a company focused on the research, development, manufacturing, sales, and marketing of pharmaceutical and regenerative medicine products. It specializes in creating treatments for spinal cord injuries and other neurological conditions, including cerebral infarction, by studying induced pluripotent stem cells. Through its innovative approach, K Pharma aims to advance therapeutic options for patients suffering from debilitating neurological disorders.
Developer of sensing devices, robot hands, and technology designed to expand the scope of application of robots and machines. The company uses its tactile technology to improve the robot's ability to move and perform the tasks that had to be handled by humans earlier, allowing industries to automate and save labor in pick-and-place processes and solve various social issues.
Modulus Co., Ltd., established in 2016 and based in Tokyo, Japan, specializes in drug discovery with a focus on developing small-molecule therapeutics for oncology, chronic inflammation, immune disorders, and rare genetic conditions. The company employs advanced computational techniques, including virtual screening and machine learning algorithms, to facilitate the rapid design and generation of drug candidates targeting high-value diseases. Modulus Discovery's innovative platform integrates biological insights with computational drug discovery expertise, allowing for dynamic simulations of proteins in solvated environments. The firm also has an office in Cambridge, Massachusetts, and boasts a team of experts in drug design and disease biology, many of whom have extensive research and development experience in leading pharmaceutical and biotechnology firms.
Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Luxonus is engaged in the development of advanced imaging devices utilizing photoacoustic technology. This innovative approach allows for the early detection and diagnosis of diseases by producing ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. The device operates safely and effectively without exposing patients to harmful radiation, as it combines optical and ultrasonic waves. By providing detailed insights into the onset of diseases, the healing process, and health conditions before and after illness, Luxonus aims to enhance the diagnostic capabilities available to healthcare professionals.
Grace Imaging specializes in advanced fatigue measurement services that utilize lactate sensing in sweat and MRI technologies. The company has developed a device designed to measure lactic acid concentration in sweat, allowing for precise fatigue analysis. By integrating sweat lactate sensors and MRI techniques, Grace Imaging offers users insights into exercise load and muscle changes, enhancing the understanding of athletic performance and recovery.
Heartseed Inc., founded in 2015 and based in Tokyo, Japan, focuses on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company aims to advance the clinical application of regenerative medicine specifically for treating heart disease. Heartseed is dedicated to creating cardiomyocyte replacement therapies derived from iPS cells to address advanced heart failure, aspiring to transform the treatment landscape for patients suffering from this condition.
Operator of a drug discovery and development company intended to make the world disease-free. The company's research leverages the power of the gut microbiome, which can be applied to fields of pharmaceutical, healthcare, functional food, and academia, enabling innovations in the treatment of patients and curing diseases.
Operator of a medical company intended to develop an ultra-compact proton cancer therapy system. The company's device utilizes radiotherapy which pinpoints and accurately irradiates tumors deep inside the body, reducing damage to normal surrounding tissues and organs, enabling doctors and clinicians to provide proton cancer therapy for better treatment at a lower cost.
AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.
Founded in 2020, Skygate Technologies is building a network to deliver a
large volume of data from observation satellites around the Earth to the
ground and integrating the network into the web architecture. “Make
Space accessible on the Web” is its motto, and the ability to develop both
hardware and software is its strength. More information about Skygate
Technologies can be found at www.skygate-tech.com.
Modulus Co., Ltd., established in 2016 and based in Tokyo, Japan, specializes in drug discovery with a focus on developing small-molecule therapeutics for oncology, chronic inflammation, immune disorders, and rare genetic conditions. The company employs advanced computational techniques, including virtual screening and machine learning algorithms, to facilitate the rapid design and generation of drug candidates targeting high-value diseases. Modulus Discovery's innovative platform integrates biological insights with computational drug discovery expertise, allowing for dynamic simulations of proteins in solvated environments. The firm also has an office in Cambridge, Massachusetts, and boasts a team of experts in drug design and disease biology, many of whom have extensive research and development experience in leading pharmaceutical and biotechnology firms.
BONX Inc. specializes in the design and development of wearable communication devices tailored for outdoor sports enthusiasts. Founded in 2014 and based in Tokyo, Japan, the company offers the BONX Grip, a Bluetooth earpiece that enables group conversations, music streaming, and phone calls. This device is particularly suited for activities such as snowboarding, cycling, stand-up paddleboarding, and fishing, featuring water and shockproof capabilities to withstand the rigors of outdoor use. BONX sells its products online, providing athletes with a reliable means to stay connected with friends while engaging in leisure and sporting activities.
APB Co., Ltd., founded in 2018 and based in Tokyo, Japan, specializes in the research, development, manufacture, and sales of advanced lithium-ion batteries. The company focuses on creating next-generation lithium-ion and all-polymer batteries designed to address existing challenges in battery technology. Through its innovative approach, APB aims to enhance battery performance and reliability, catering to various sectors that require efficient energy storage solutions.
Kringle Pharma, Inc. is a biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF) protein medicines and NK4 molecules. Established in 2001 and headquartered in Japan, the company aims to harness the regenerative properties of HGF for various medical conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scarring. In addition to HGF, Kringle Pharma develops NK4, which acts as an antagonist to HGF and exhibits anti-cancer properties by inhibiting tumor cell invasion and metastasis. The company's product pipeline includes recombinant human HGF for treating acute renal failure, skin ulcers, and central nervous system disorders, as well as NK4 and NK4 gene therapies for cancer treatment.
Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Luxonus is engaged in the development of advanced imaging devices utilizing photoacoustic technology. This innovative approach allows for the early detection and diagnosis of diseases by producing ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. The device operates safely and effectively without exposing patients to harmful radiation, as it combines optical and ultrasonic waves. By providing detailed insights into the onset of diseases, the healing process, and health conditions before and after illness, Luxonus aims to enhance the diagnostic capabilities available to healthcare professionals.
Synspective Inc., based in Tokyo, Japan, specializes in satellite data technology that integrates synthetic aperture radar (SAR) satellite constellations, big data, and machine learning. The company offers remote sensing and satellite imagery services using small-sized SAR satellites, which can monitor human activity across vast areas regardless of time or weather conditions. Its technology is designed to support various sectors, including urban design, infrastructure, energy, insurance, and finance, helping clients meet their sustainable development and resilient urban development objectives. Synspective stands out with its high frequency, resolution, and responsiveness in satellite data provision.
Motion Lib, Inc. is a Japanese company specializing in haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 in Kawasaki, the company initially operated under the name Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib develops advanced chips that estimate and calculate the repulsive force experienced when objects are touched, based on the load force applied to robotic motors. This innovative technology facilitates the integration of machines into various sectors, thereby expanding their operational capabilities and contributing to overall societal productivity.
Instalimb, Inc. is a Tokyo-based company specializing in the development of low-cost prosthetics through advanced technologies such as 3D computer-aided design, 3D printing, and machine learning. As the world's first business focused on 3D printed prostheses, Instalimb aims to make prosthetic devices more accessible and affordable for individuals in need. The innovative approach combines cutting-edge technology with a commitment to improving the quality of life for users, setting a new standard in the prosthetic industry.
Xenodata Lab, Co., Ltd., founded in 2012 and based in Tokyo, Japan, specializes in artificial intelligence-driven data analysis. The company develops a platform that transforms unstructured data from financial reports into structured, table-format data, enhancing accuracy and accessibility for users. By focusing on economic forecasts and financial document analysis, Xenodata Lab enables businesses to effectively interpret and utilize information following financial results announcements. The company aims to advance the financial industry through innovative technology and the efficient processing of data, emphasizing the potential of AI to enhance human decision-making in this sector.
Luxonus is engaged in the development of advanced imaging devices utilizing photoacoustic technology. This innovative approach allows for the early detection and diagnosis of diseases by producing ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. The device operates safely and effectively without exposing patients to harmful radiation, as it combines optical and ultrasonic waves. By providing detailed insights into the onset of diseases, the healing process, and health conditions before and after illness, Luxonus aims to enhance the diagnostic capabilities available to healthcare professionals.
Himuka AM Pharma is a pharmaceutical company based in Miyazaki City, Japan, founded in February 2017. The company focuses on the research, development, and discovery of new drug seeds aimed at enhancing adrenomedullin, a peptide involved in various physiological processes. Through its innovative approach, Himuka AM Pharma seeks to contribute to advancements in medical treatments and improve health outcomes.
CureApp is a digital health startup.The firm is one of the leading players in the medical app vertical under the theme of “app exhibits therapeutic effects against diseases” and launched a nicotine addiction treatment app in February 2015, which was jointly developed with Division of Pulmonary Medicine, Keio University’s School of Medicine. It is currently conducting clinical trials in many locations.
BONX Inc. specializes in the design and development of wearable communication devices tailored for outdoor sports enthusiasts. Founded in 2014 and based in Tokyo, Japan, the company offers the BONX Grip, a Bluetooth earpiece that enables group conversations, music streaming, and phone calls. This device is particularly suited for activities such as snowboarding, cycling, stand-up paddleboarding, and fishing, featuring water and shockproof capabilities to withstand the rigors of outdoor use. BONX sells its products online, providing athletes with a reliable means to stay connected with friends while engaging in leisure and sporting activities.
Tsubota Laboratory, Inc. is a Tokyo-based company founded in 2015 that focuses on the research and development of innovative treatments for dry eye, myopia, and presbyopia. The company specializes in creating pharmaceutical products and medical devices, as well as developing dietary supplements aimed at alleviating dry eye symptoms. Through its efforts, Tsubota Laboratory aims to provide effective solutions to enhance eye health and improve the quality of life for individuals suffering from these conditions.
Institution for a Global Society is a a French graduate school with students from 70 countries around the world
IDAC Theranostics, Inc. engages in research, development, and production of pharmaceutical products for the treatment of cancer, graft-versus-host disease (GVHD), inflammation diseases, diagnostics, and other diseases. The company was founded in 2012 and is based in Tokyo, Japan.
Motion Lib, Inc. is a Japanese company specializing in haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 in Kawasaki, the company initially operated under the name Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib develops advanced chips that estimate and calculate the repulsive force experienced when objects are touched, based on the load force applied to robotic motors. This innovative technology facilitates the integration of machines into various sectors, thereby expanding their operational capabilities and contributing to overall societal productivity.
Generic Solution Corporation provides software distribution services. The company also provides data analytics and artificial intelligence services. Generic Solution Corporation was founded in 2006 and is based in Tokyo, Japan.
BONX Inc. specializes in the design and development of wearable communication devices tailored for outdoor sports enthusiasts. Founded in 2014 and based in Tokyo, Japan, the company offers the BONX Grip, a Bluetooth earpiece that enables group conversations, music streaming, and phone calls. This device is particularly suited for activities such as snowboarding, cycling, stand-up paddleboarding, and fishing, featuring water and shockproof capabilities to withstand the rigors of outdoor use. BONX sells its products online, providing athletes with a reliable means to stay connected with friends while engaging in leisure and sporting activities.
CureApp is a digital health startup.The firm is one of the leading players in the medical app vertical under the theme of “app exhibits therapeutic effects against diseases” and launched a nicotine addiction treatment app in February 2015, which was jointly developed with Division of Pulmonary Medicine, Keio University’s School of Medicine. It is currently conducting clinical trials in many locations.
AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.
Quan Inc. develops content for smartphone applications and web. The company develops characters contents such as Betakkuma, Sugar Cubs, Business Fish, Piyomaru, sticker shop for au Smartpass, Mr.Egg, Elice, Kawaii Kaomoji Book, handwritten stickers, AIS MystickerShop and game contents that includes emotipon. The company offers characters for mobile carriers, chatting applications and platforms of Japan and Southeast Asian nations. Quan Inc. was founded in 2011 and is based in Tokyo, Japan.
Kringle Pharma, Inc. is a biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF) protein medicines and NK4 molecules. Established in 2001 and headquartered in Japan, the company aims to harness the regenerative properties of HGF for various medical conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scarring. In addition to HGF, Kringle Pharma develops NK4, which acts as an antagonist to HGF and exhibits anti-cancer properties by inhibiting tumor cell invasion and metastasis. The company's product pipeline includes recombinant human HGF for treating acute renal failure, skin ulcers, and central nervous system disorders, as well as NK4 and NK4 gene therapies for cancer treatment.
SENSY Inc. is a Tokyo-based company founded in November 2011 that focuses on personal artificial intelligence designed to enhance user experiences by understanding individual sensitivities. The company offers business-to-consumer and business-to-business services, as well as support for launching new business-related offerings. By leveraging its AI technology, SENSY aims to create meaningful and transformative interactions that cater to the diverse lifestyles of its users.